drugset
drugset / Trial / NCT05068947

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

NCT05068947 ↗

Phase 1 Completed 16 enrolled Graviton Bioscience Corporation
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.

Timeline

Start
2021-09-10
Primary completion
2021-10-22
Completion
2021-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject GV101 Unknown 50 mg Oral
Subject GV101 Unknown 100 mg Oral
Subject GV101 Unknown 200 mg Oral
Subject GV101 Unknown 400 mg Oral
Subject GV101 Unknown 800 mg Oral
Subject GV101 Unknown 1600 mg Oral

Indications

No indication recorded.